In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects
- PMID: 8627733
- PMCID: PMC190036
- DOI: 10.1128/JVI.70.3.2038-2043.1996
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects
Abstract
We have evaluated the sequence diversity of the protease human immunodeficiency virus type 1 in vivo. Our analysis of 246 protease coding domain sequences obtained from 12 subjects indicates that amino acid substitutions predicted to give rise to protease inhibitor resistance may be present in patients who have not received protease inhibitors. In addition, we demonstrated that amino acid residues directly involved in enzyme-substrate interactions may be varied in infected individuals. Several of these substitutions occurred in combination either more or less frequently than would be expected if their appearance was independent, suggesting that one substitution may compensate for the effects of another. Taken together, our analysis indicates that the human immunodeficiency virus type 1 protease has flexibility sufficient to vary critical subsites in vivo, thereby retaining enzyme function and viral pathogenicity.
Similar articles
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266. Virology. 1996. PMID: 8638406
-
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.J Virol. 1996 Dec;70(12):8270-6. doi: 10.1128/JVI.70.12.8270-8276.1996. J Virol. 1996. PMID: 8970946 Free PMC article.
-
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.J Virol. 1994 Mar;68(3):2016-20. doi: 10.1128/JVI.68.3.2016-2020.1994. J Virol. 1994. PMID: 8107264 Free PMC article.
-
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.AIDS Rev. 2008 Jul-Sep;10(3):131-42. AIDS Rev. 2008. PMID: 18820715 Free PMC article. Review.
-
Inhibitors of HIV-1 protease.J Enzyme Inhib. 1992;6(1):65-98. doi: 10.3109/14756369209041357. J Enzyme Inhib. 1992. PMID: 1285304 Review.
Cited by
-
Few mutations in the 5' leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses.J Virol. 2005 May;79(9):5421-7. doi: 10.1128/JVI.79.9.5421-5427.2005. J Virol. 2005. PMID: 15827156 Free PMC article.
-
Linkage disequilibrium test implies a large effective population number for HIV in vivo.Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10758-63. doi: 10.1073/pnas.96.19.10758. Proc Natl Acad Sci U S A. 1999. PMID: 10485899 Free PMC article.
-
Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology.Microbiol Mol Biol Rev. 2001 Mar;65(1):151-85. doi: 10.1128/MMBR.65.1.151-185.2001. Microbiol Mol Biol Rev. 2001. PMID: 11238990 Free PMC article. Review.
-
Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Virology. 2008 Sep 1;378(2):272-81. doi: 10.1016/j.virol.2008.05.029. Epub 2008 Jul 2. Virology. 2008. PMID: 18599104 Free PMC article.
-
Rapid turnover of intra-host genetic diversity in Zucchini yellow mosaic virus.Virus Res. 2011 Feb;155(2):389-96. doi: 10.1016/j.virusres.2010.11.007. Epub 2010 Dec 4. Virus Res. 2011. PMID: 21138748 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical